TARA

Protara Therapeutics' stock has been impacted by clinical data presentations, financial results announcements, regulatory milestones, a public offering, and participation in investor conferences. Interim results from the ADVANCED-2 trial showed a 68% complete response rate at six months in BCG-unresponsive bladder cancer patients. TARA-002 received Fast Track and Breakthrough Therapy designations from the FDA for treating pediatric patients with macrocystic and mixed cystic lymphatic malformations. The company completed an oversubscribed $86 million public offering. Over the past 52 weeks, TARA stock has traded between $2.77 and $7.82, with a share price of $5.45 as of May 4, 2026.